Antibody Discovery Services — B Cell, Phage Display & Hybridoma
Diversity-focused discovery, empowering data-driven down-selection
AVS Bio's antibody discovery service provides B cell selection, phage display, and hybridoma technologies to generate diverse panels of high-quality antibody hits, with early-stage functional characterization built into the workflow. Platforms are selected based on target type, required antibody diversity, and downstream application — or combined where programs benefit from orthogonal approaches.
Resource:
B cell Selection
Our B cell selection platform offers a powerful approach to explore the full spectrum of antibodies produced by an animal's immune system. It supports antibody generation from all species available at AVS Bio and enables comprehensive screening across all antibody types.
Antibodies can be selected against recombinant proteins, cell-expressed targets, VLPs/membrane-mimetics (complex targets), peptides and small molecules. The platform facilitates high-throughput (functional) screening of up to a million single B-cells a day, accelerating the identification of hits. By applying NGS-based sequencing, a large number of hits can be further characterized to accelerate and improve discovery program success.
Resources:
- Poster "Harnessing diversity-focused mouse B cell discovery and early stage, high-throughput characterization"
- Poster "Advancing VHH discovery leveraging a high throughput B cell-based platform"
Phage Display - DeepDisplay
Phage display is a powerful technique for selecting antibodies that require specific characteristics, such as epitope-specificity, isoform/species cross-reactivity, or ligand-competing potential. AVS Bio offers ready-to-use human naive and autoimmune patient-derived (scFv) repertoires as well as naïve (VHH) repertoires from camelids. These off-the-shelf libraries offer the fastest route to discovery of fully human therapeutic antibodies.
AVS Bio also generates custom immune libraries from all available species at AVS Bio as well as from transgenic animals (DeepDisplay). These immune libraries capture virtually the entire V-gene repertoire from these species. Following sequencing of target-reactive clones, selected antibody fragments can easily be re-formatted into any antibody format, such as full-size IgG and bispecifics. The scFv or VHH nature of the repertoires allow for easy re-formatting for CAR-T approaches as well.
Resource:
Rare Hit Magnification
Our Rare Hit Magnification Platform is capable of identifying the "needle in a haystack" within larger repertoires. The platform mines the full output of each phage selection round, overcoming the well-known growth limitations in E. coli.
By applying next-generation sequencing (NGS) to full phage outputs, we capture the complete spectrum of hits — not just the more abundant ones. This powerful enhancement ensures that no opportunity is overlooked, allowing clients to extract maximum value from every phage display project. In addition, our rapid scFv to hIgG re-formatting approach significantly accelerates the hit validation process of the NGS-identified rare hits.
Hybridoma — Subcloning Free
AVS Bio offers hybridoma services for both mouse and rat. By growing hybridomas in our proprietary, semi-solid media, we can immediately pick single cell colonies post fusion. Therefore, hybridomas are monoclonal as early as possible, supporting the rapid characterization, expansion, and cryopreservation of hybridomas of interest.
Platform selection guide:
Frequently Asked Questions
Q: What is the difference between B cell selection, phage display, and hybridoma for antibody discovery?
A: B cell selection screens individual B cells from immunized animals, enabling high-throughput identification of rare, naturally occurring antibodies with strong binding characteristics. Phage display captures the whole antibody repertoire of an animal and presents antibody fragments on bacteriophage surfaces for in vitro selection, useful for targets that are difficult to immunize against. Hybridoma technology fuses B cells with myeloma cells to create immortalized cell lines producing a single monoclonal antibody. AVS Bio offers all three platforms and recommends the approach based on target type, required diversity, and downstream application.
.avif)
